Cargando…

Efficacy and safety of Paxlovid for COVID-19:a meta-analysis

Detalles Bibliográficos
Autores principales:	Zheng, Qian, Ma, Pengfei, Wang, Mingwei, Cheng, Yongran, Zhou, Mengyun, Ye, Lan, Feng, Zhanhui, Zhang, Chunlin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Infection Association. Published by Elsevier Ltd. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523907/ https://www.ncbi.nlm.nih.gov/pubmed/36191676 http://dx.doi.org/10.1016/j.jinf.2022.09.027

Ejemplares similares

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis
por: Wen, Wen, et al.
Publicado: (2022)

Safety and efficacy of the COVID-19 vaccine in children and/or adolescents:A meta-analysis
por: Xu, Wencheng, et al.
Publicado: (2022)

Antibody response and safety of COVID-19 vaccine in peritoneal dialysis patients
por: Zheng, Qian, et al.
Publicado: (2022)

A meta-analysis of the association between calprotectin and the severity of COVID-19
por: Mao, Qin, et al.
Publicado: (2022)

Meta-analysis of post-traumatic stress disorder and COVID-19 in patients discharged
por: Chen, Chen, et al.
Publicado: (2022)

Post-COVID-19 fatigue among COVID-19 in patients discharged from hospital: A meta-analysis
por: Ji, Guohua, et al.
Publicado: (2022)

Multidrug-resistant infection in COVID-19 patients: A meta-analysis
por: Hu, Siqi, et al.
Publicado: (2023)

Efficacy and safety of outpatient parenteral antibiotic therapy in patients with infective endocarditis: a meta-analysis
por: Wen, Wen, et al.
Publicado: (2022)

Efficacy of Paxlovid in patients with acute kidney injury who developed COVID-19
por: Cai, Hong, et al.
Publicado: (2022)

Elevated troponin levels predict the reduced efficacy of Paxlovid in COVID-19 patients
por: Zhao, Deze, et al.
Publicado: (2023)

Olfactory dysfunction after COVID‐19: metanalysis reveals persistence in one-third of patients 6 months after initial infection
por: Hu, Siqi, et al.
Publicado: (2023)

Gut Microbial Characteristics of Adult Patients With Epilepsy
por: Dong, Lian, et al.
Publicado: (2022)

Downregulating NHE-1 decreases the apoptosis of hippocampal cells in epileptic model rats based on the NHE-1/calpain1 pathway
por: Peng, Shuang, et al.
Publicado: (2023)

Safety of SARS-CoV-2 vaccines in patients with myasthenia gravis: a meta-analysis
por: Zheng, Qian, et al.
Publicado: (2023)

Safety of COVID-19 vaccine in patients with epilepsy: a meta-analysis
por: Zheng, Qian, et al.
Publicado: (2022)

Rapid COVID-19 rebound in a severe COVID-19 patient during 20-day course of Paxlovid
por: Wang, Yu, et al.
Publicado: (2022)

Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities
por: Dian, Yating, et al.
Publicado: (2023)

Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis
por: Wen, Wen, et al.
Publicado: (2022)

Explore the attitudes of children and adolescent parents towards the vaccination of COVID-19 in China
por: Wang, Lin, et al.
Publicado: (2022)

Medical emergency calls and calls for central nervous system symptoms during the COVID-19 outbreak in Hangzhou, China
por: Fu, Xinyan, et al.
Publicado: (2022)

Projected COVID-19 Mortality Reduction From Paxlovid Rollout
por: Khunte, Mihir, et al.
Publicado: (2023)

The Path to Paxlovid
por: Halford, Bethany
Publicado: (2022)

Efficacy of Paxlovid and Lagevrio for COVID-19 Infection in Patients With Inflammatory Bowel Disease: A Propensity-Matched Study
por: Hashash, Jana G., et al.
Publicado: (2023)

The future of Paxlovid for COVID-19
por: Burki, Talha
Publicado: (2022)

Safety and Efficacy of Paxlovid Against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients
por: Weng, Chengzhao, et al.
Publicado: (2023)

Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
por: Sánchez Fabra, David, et al.
Publicado: (2023)

Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
por: Sánchez Fabra, David, et al.
Publicado: (2023)

Food Safety Knowledge, Attitudes, and Self-Reported Practices Among Medical Staff in China Before, During and After the COVID-19 Pandemic
por: Luo, Lin, et al.
Publicado: (2021)

Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study
por: Liu, Jiao, et al.
Publicado: (2023)

Ranolazine Toxicity Secondary to Paxlovid
por: Casey, Bradley, et al.
Publicado: (2023)

Impact of Paxlovid on international normalized ratio among patients on chronic warfarin therapy
por: Muse, Oluwatoyosi, et al.
Publicado: (2022)

Paxlovid with Caution: Novel Case of Paxlovid-Induced Tacrolimus Toxicity in a Cardiac Transplant Patient
por: Shah, Aaisha, et al.
Publicado: (2022)

Efficacy and safety of tocilizumab in hospitalized COVID-19 patients: A systematic review and meta-analysis
por: Luo, Lili, et al.
Publicado: (2022)

Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients: A systematic review and meta-analysis
por: Cheema, Huzaifa Ahmad, et al.
Publicado: (2022)

Activation of PXR causes drug interactions with Paxlovid in transgenic mice
por: Lei, Saifei, et al.
Publicado: (2023)

Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients
por: Chen, Ping-Jen, et al.
Publicado: (2021)

The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6–14 years: a cohort study
por: Yan, Gangfeng, et al.
Publicado: (2022)

Paxlovid™ jetzt direkt an Patienten abgeben
por: Zimmermann, Gerd W.
Publicado: (2022)

Paxlovid-Induced Symptomatic Bradycardia and Syncope
por: Ganipisetti, Venu M, et al.
Publicado: (2023)

CARDIOGENIC SHOCK DUE TO PAXLOVID INTERACTION
por: Enstrom, Cate, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7sv2ibcnr6v2qnuh44bfn5kmdq